Premium
Assay of gene expression in patients with major depressive disorders treated with antidepressant, Citalopram¢ç
Author(s) -
Kim In kyoung,
Lee SeungHo,
Kim KiNam,
Kang RheeHun,
Ham ByungJoo,
Shin KyungHo,
Lee MinSoo,
Kim MeyoungKon
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.lb77
Subject(s) - citalopram , antidepressant , gene , gene expression , microarray , complementary dna , dna microarray , microarray analysis techniques , biology , signal transduction , medicine , pharmacology , genetics , hippocampus
Purpose: The aim of this study was to assess the differences in gene expression profiles in Citalopram‐treated patients with major depression at 4th and 8th week. Methods: This study included 10 patients with major depression, and 8 healthy controls. To examine the differences of gene expression profile in depression patients, radioactive cDNA microarrays were used to evaluate changes in the expression of 1,152 genes in total. Using ©ø©øP‐labeled probes, this method provided highly sensitive gene expression profiles. Results: Gene transcription profiles were classified into several categories in accordance with the antidepressant gene‐regulation. These data demonstrate that genes such as serotonin receptor 2A, dopa decarboxylase, and other signal transduction related genes were down regulated and the gene of GABA B receptor was up regulated in citalopram negative group compared to citalopram positive group. Conclusions: These results suggest that antidepressants interfere with the expression of a large array of genes. involved in signaling, survival and protein metabolism. And radioactive human cDNA microarray may have far‐reaching applications for new drug development and personalized medicines.